Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467818 · ClinicalTrials.gov registry record · NA
Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders
A NA study, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00467818 is a NA study that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 17 participants.
The verdict
NCT00467818, a NA study, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: * Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. * Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. * Omega 3 fatty acids will be superior to placebo in improving functional ability.
Interventions
- OTHER Placebo
- DRUG Omega 3 fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467818
The ClinicalTrials.gov registry entry for NCT00467818 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00467818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00467818 about?
NCT00467818 is a clinical study titled "Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders". Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D sc...
What is the current status of trial NCT00467818?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2007-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00467818?
The interventions under investigation include: Placebo (OTHER), Omega 3 fatty acids (DRUG).
Who is sponsoring clinical trial NCT00467818?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.